title: A Single-Center Experience With Brentuximab Vedotin in Gamma Delta T-Cell Lymphoma.
authors.affiliation: Department of Dermatology and Dermatopathology, University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: rtalpur@mdanderson.org.
authors.forename: Rakhshandra
authors.initials: R
authors.lastname: Talpur
authors.affiliation: University of Texas Medical School, Houston, TX.
authors.forename: Ramya
authors.initials: R
authors.lastname: Chockalingam
authors.affiliation: Department of Dermatology and Dermatopathology, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Casey
authors.initials: C
authors.lastname: Wang
authors.affiliation: University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Michael T
authors.initials: MT
authors.lastname: Tetzlaff
authors.affiliation: Department of Dermatology and Dermatopathology, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Madeleine
authors.initials: M
authors.lastname: Duvic
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000079963:Brentuximab Vedotin; D005260:Female; D006801:Humans; D018796:Immunoconjugates / Q000648:ultrastructure*; D017730:Ki-1 Antigen / Q000378:metabolism; D016399:Lymphoma, T-Cell / Q000188:drug therapy* / Q000378:metabolism; D008875:Middle Aged
chemical_list: D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin
keywords: Anaplastic large cell lymphoma; CD30 expression; Primary cutaneous lymphomas; Sensory peripheral neuropathy; Stem cell transplant